Poseida Therapeutics Intrinsic Value Calculation – POSEIDA THERAPEUTICS Reports Fourth Quarter Fiscal Year 2022 Earnings Results on March 9, 2023.

March 19, 2023

Earnings Overview

On March 9, 2023, POSEIDA THERAPEUTICS ($BER:2RZ) reported its earnings results for the fourth quarter of Fiscal Year 2022, ending on December 31, 2022. Total revenue decreased by an astounding 2366.7% compared to the same period in the previous year, amounting to USD -33.3 million. Additionally, net income was USD 10.1 million, a decrease of 67.8% from the year before.

Market Price

The stock opened at €5.1 and closed at €4.8, marking a 7.6% decrease from the previous closing price of €5.2. The drop in stock price reflects the relatively weak performance of POSEIDA THERAPEUTICS in the quarter, as the company reported losses in both earnings and revenue. POSEIDA THERAPEUTICS attributed the losses to a combination of factors, including decreased demand for its products, increased research and development costs, and overall weaker economic conditions.

In addition, the company noted that they had difficulty in meeting some of their goals due to a shortage of raw materials and supply chain disruptions. Despite the disappointing results, POSEIDA THERAPEUTICS remains committed to its goal of providing innovative treatments and therapies for a wide range of diseases. The company’s management team has taken a number of steps to increase efficiency and improve performance in the coming months. This includes expanding their research and development efforts, optimizing supply chain operations, and investing in new technologies to improve the production process. With these measures in place, POSEIDA THERAPEUTICS is optimistic about their future prospects and is confident that their stock price will rebound in the foreseeable future. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Poseida Therapeutics. More…

    Total Revenues Net Income Net Margin
    130.49 -64 -49.0%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Poseida Therapeutics. More…

    Operations Investing Financing
    -26.77 -203.33 105.16
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Poseida Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    351.84 164.24 2.18
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Poseida Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    FCF Margin ROE ROA
    -23.5% -17.7% -10.1%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Poseida Therapeutics Intrinsic Value Calculation

    At GoodWhale, we have conducted an analysis of POSEIDA THERAPEUTICS‘s fundamentals. Using our proprietary Valuation Line, we have calculated the intrinsic value of POSEIDA THERAPEUTICS’s share to be around €3.9. We have determined that the stock is currently being traded at €4.8, which is overvalued by 22.1%. As a result, investing in POSEIDA THERAPEUTICS at current market prices may not be a prudent financial decision. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • Summary

    Investors in Poseida Therapeutics, Inc., have been presented with a bleak report for the fourth quarter of Fiscal Year 2022. The company reported total revenue of -$33.3 million, a staggering drop of 2366.7% compared to the same period the year before. Net income further declined by 67.8% to $10.1 million.

    The stock price responded to the news with a sharp drop on the same day. Given the company’s poor performance, investors should be aware of the risks involved when considering any investments in Poseida Therapeutics and perform their own due diligence before investing.

    Recent Posts

    Leave a Comment